Filing Flows › Health Care › Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals (SUPN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · Supernus Pharmaceuticals (SUPN) Q3 2026 earnings results →
Q3 2026 Revenue up 18% year over year to $227M · 9¢ of every $1 of revenue kept as net profit · operating margin 9.3%
Supernus Pharmaceuticals made $227M in Q3 2026 (+18% Y/Y): Net product sales $179M, ONAPGO $17.1M, Trokendi XR $10.2M. Operating margin 9.3%, net earnings $20.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $226.8M in Q3 2026, up 18% year over year and up 4% from the previous quarter. Qelbree was the largest line at 40% of revenue. Collaboration revenue (ZURZUVAE) added $21.5M year over year (up 107%), 62% of the total change. Other declined 52%.
Operating profit was $21.2M, a 9.3% margin (up 40.7 points year over year). Total costs fell 19% while revenue rose 18%. The fastest-growing cost line was Cost of revenue (+42%). Net earnings were $20.9M. The effective tax rate was 7.9%.
Operating cash flow was $6.6M, 32% of net earnings. Non-cash charges added back $23.6M of depreciation and amortization and $8.9M of share-based compensation. Working capital and other items used $46.9M. Capital expenditures of $230K left free cash flow of $6.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 29, 2026 | $227M | +18% | 9.3% | $20.9M | $6.6M |
| Q2 2026 | 10-Q | Aug 3, 2026 | $219M | +32% | -26.5% | −$58.4M | −$4.8M |
| Q1 2026 | 10-Q | May 5, 2026 | $208M | +39% | -4.0% | −$2.3M | $66.5M |
| Q4 2025 | 10-K | Mar 2, 2026 | $212M | +22% | -1.9% | −$4.1M | $19.9M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $192M | +9% | -31.4% | −$45.1M | −$61.7M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $165M | -2% | 7.3% | $22.5M | $58.5M |
| Q1 2025 | 10-Q | May 6, 2025 | $150M | +4% | -6.8% | −$11.8M | $30.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.
In its own words, from its 10-K, filed Mar 2, 2026.
Supernus Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +18% against the peers' median +10%. Operating margin: 9.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Q3 2026 | $227M | +18% | 9.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Supernus Pharmaceuticals 10-Q on SEC EDGAR · CIK 1356576 · Pharmaceutical Preparations
13F: who owns SUPN and who is buying
More on SUPN
- How Supernus Pharmaceuticals makes money: revenue by segment
- Supernus Pharmaceuticals next earnings date and what analysts expect
- Supernus Pharmaceuticals stock forecast, price target and fair value
- Who owns Supernus Pharmaceuticals stock: holders, funds and Congress trades
- Supernus Pharmaceuticals guidance and outlook
- Is Supernus Pharmaceuticals a takeover target? LBO and rumors
- Supernus Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Supernus Pharmaceuticals guidance history: guided vs reported
- Supernus Pharmaceuticals free cash flow by quarter
- Supernus Pharmaceuticals R&D spending by quarter
- Supernus Pharmaceuticals capital expenditures by quarter
- Supernus Pharmaceuticals Net product sales revenue by quarter
- Supernus Pharmaceuticals ONAPGO revenue by quarter
- Supernus Pharmaceuticals Trokendi XR revenue by quarter